Seeking Alpha

Celgene's (CELG -0.1%) Apremilast drug significantly improved the signs and symptoms of patients...

Celgene's (CELG -0.1%) Apremilast drug significantly improved the signs and symptoms of patients with psoriatic arthritis in the company's "Palace 3" Phase III study. The results come a day after Celgene reported a positive outcome from "Palace I". In total, the company is conducting four Phase III "Palace" trials. (PR)
Comments (1)
  • heffera
    , contributor
    Comments (6) | Send Message
     
    somewhat expected, but should have a beneficial effect on FDA approval. As a non-biologic, it has other treatment merits as well.
    13 Jun 2013, 02:31 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector